Proactively recruited by this startup organization to launch Carvykti, a CAR-T therapy for myeloma. Maintain ongoing responsibility for strategically managing the relationship between Legend Biotech and its key customers in growing the business by understanding their business strategies and initiatives, and selling our solutions that bring value to the customer. Cultivate and foster strategic relationships with senior leaders throughout North Texas, Oklahoma and Arkansas.Leadership Engagement▬▬▬▬▬▬▬▬▬▬▬✔Effectively drive multiple myeloma CAR-T brand choice amongst institutional-based oncology customers.✔Provide valuable feedback and insights to cross-functional team from interactions with healthcare professionals, including account business trends and potential changes in the therapeutic landscape to effectively advance the Legend Biotech brand.Select Achievements▬▬▬▬▬▬▬▬▬✔Ranked #6 in the nation and #3 in the region, 2023 exceeding goal by XXX%.✔Conducted all aspects of pre-launch activities including account planning, profiling, and KOL development, 2022. ✔Selected for and completed the company’s first-ever “Emerging Leaders” program.

Promoted Lenvima for Renal, Liver, Thyroid and Endometrial cancer to key community oncology accounts and IDNs in North Texas. Leadership Engagement▬▬▬▬▬▬▬▬▬▬▬✔Developed and implemented account plans and aligned on strategic priorities with key account stakeholders including the C-Suite, Vice Presidents, and Directors. ✔Cultivated alliances with internal colleagues and effectively mobilized the matrix team to execute pull-through strategies.Select Achievements▬▬▬▬▬▬▬▬▬✔Grew account performance from 87.8% of goal attainment in June 2020 to 105.5% by December 2020.✔Executed three virtual programs, despite accounts being closed to industry due to the COVID-19 pandemic.✔Worked with director-level personnel in key accounts to develop and implement programs for improved adherence, compliance and patient-reported outcome collection.

Key Account Manager for oncology accounts in North Texas, New Mexico, and Colorado, including the launch of Darzalex, Darzalex Faspro, Imbruvica, Erleada, Zytiga, and Yondelis. Marketed and promoted products to community Oncology practices, teaching institutions, and hospitals. Cultivated alliances to advance the use of our brands in oncology and improve the company’s position as a strategic partner. Collaborated with brand teams in the creation of value propositions for core products.Leadership Engagement▬▬▬▬▬▬▬▬▬▬▬✔Served as a subject matter expert in emerging trends in healthcare including Alternative Payment Models, the Triple Aim, PQRS, Healthcare Reform, Medicaid Expansion, Patient Experience Programs, Formulary and Pathways, and Affordability under both the medical and pharmacy benefits.✔Collborated with the National Account Director to support oncology-focused physician GPO meetings and contract rollout. Select Achievements▬▬▬▬▬▬▬▬▬✔Awarded President’s Circle 2016, ranked #1 of 29 Key Account Managers in the nation.✔Developed strategic account plans for select accounts including, Texas Oncology, UT Southwestern, University of New Mexico Cancer Center, and Rocky Mountain Cancer Center.✔Recognized for effective partnering example.✔Facilitated a meeting between Texas Oncology’s executive leadership and Johnson & Johnson focusing on shifting to value-based care and how our products could help. Spearheaded a program for oral oncolytic adherence and compliance, 2019.✔Selected to complete a preceptorship with the Strategic Customer Group focusing on GPO account management which resulted in Darzalex being added to McKesson’s Clear Value Plus Pathway for all indications, 2018.✔Increased Zytiga market share to 73% compared to the national average of 54%, 2017.✔Grew total portfolio by 129% (9% better than company average), 2017.

Worked collaboratively with internal and external stakeholders to promote Imbruvica, Zytiga, Procrit, Nucynta, and Doxil to accounts in the greater Dallas, Texas market. Provided detailed cost analyses of EPO Stimulating Agents in oncology, nephrology and hospitals. Leadership Engagement▬▬▬▬▬▬▬▬▬▬▬✔Presented to key customers on topics including Medicare Overview, Working with Specialty Pharmacy, Navigating Exceptions and Appeals, Emerging Trends in Healthcare, Considerations for Proactive Practice Management, and Considerations for In-Office Dispensing.✔Worked collaboratively with internal sales management to set sales strategies and deliver field training.✔Partnered with the strategic market director and national account directors, calling on GPOs including ION, Cardinal, Raintree, and UroGPO. Presented and negotiated contracts and educated field sales team.✔Role included extensive field reimbursement responsibilities as well. Select Achievements▬▬▬▬▬▬▬▬▬✔2014 winner of Infinity Cup Award for top district in the Region.✔Awarded Platinum Encore Award for work with training department during launch of Zytiga, 2012. ✔Partnered with Urology San Antonio to establish an in-office dispensing pharmacy, the first for Urology in the state of TX, 2015.✔Served as the Field Learning Advisor for the Area Business Specialists team.✔Recognized as a high potential leader within the organization and selected to complete the Rutgers Center for Management Development for Policy Excellence, 2013.

After the Nephrology franchise was dissolved, retained by the organization and selected as one of only 18 individuals in the nation to pilot this healthcare solution for the Oncology franchise in a new role. Responsible for promoting Procrit, Doxil, and Nucynta in oncology clinics and hospitals in Dallas, TX, as well as Procrit in Nephrology. Selected to work on internal and external special projects.Leadership Engagement▬▬▬▬▬▬▬▬▬▬▬✔Conducted a detailed analysis of the true market potential of Nucynta in oncology and proposed an equitable compensation plan.✔Worked with a hospital in the territory to develop a bloodless medicine protocol for patients undergoing elective, non-cardiac, non-vascular surgeries.Select Achievements▬▬▬▬▬▬▬▬▬✔Finished 2010 ranked #33 of 164 in the nation.

Managed a district of seven territories, covering six states promoting an injectable biologic (Procrit) for the Nephrology and Long-Term Care markets, as well as an infusible IV product in the hospital market. Provided leadership for a team of seven territory managers.Select Achievements▬▬▬▬▬▬▬▬▬▬▬▬▬▬✔Regional Infinity Cup winner for 2008 for top district, taking the district from #3 of 4, to #1 of 4 in 6 months. This was achieved through intensive coaching, mentoring, and motivating of staff and instituting a focus on promoting to long-term care facilities. ✔Awarded Teal Diamond Award for 2008 for outstanding District Manager in the Region. (Cont. P3)✔Winner of national LTC contest 2009.✔Promoted multiple Territory Managers to higher positions within the organization during tenure. ✔Two territories were awarded President’s Cup Award in 2008 and 2009.✔Recipient of a Silver Encore Award for leadership in 2009.

Promoted an injectable biologic (Procrit) for the Nephrology, Internal Medicine, and Long-Term Care markets in Palm Springs, California. Account responsibilities included contract management in a buy-and-bill environment, as well as assisting accounts in utilizing specialty pharmacies.Leadership Engagement▬▬▬▬▬▬▬▬▬▬▬▬▬▬✔Selected to complete the company’s Management Development Program in November 2007.✔Trained and mentored a college over-hire who went on to win back-to-back President’s Cup awards.✔Promoted to Sr. Product Specialist in 2006 and promoted to Territory Manager in 2007.Select Achievements▬▬▬▬▬▬▬▬▬▬▬▬▬▬✔Finished in top 25% of the nation each year.✔Awarded “Gold Encore Award” for conducting a POA meeting for the Los Angeles District in May 2008.✔Recipient of a “Gold Encore Award” for performing as the Interim District Manager in the Denver District.✔Awarded a “Platinum Encore Award” in 2018 for winning “Project Access.”✔President’s Cup Award winner, 2006 ranking #6 in the nation of 333 reps.

Partnered with health care professionals in the primary care setting in Palm Springs, CA to influence them to appropriately identify and treat patients in given therapeutic areas. Select Achievements▬▬▬▬▬▬▬▬▬▬▬▬▬▬✔Finished 2004 ranked #6 in the nation out of 526 in Strattera performance (top 2%).✔Finished 2003 ranked #15 in the nation out of 526 in total portfolio performance (#4 in the West Area, Top 3%). ✔Awarded “Strattera Leadership Circle” by achieving ADHD market share leadership within six months of product launch in 2003.✔Selected by peers for District MVP Award, 2003.✔Finished 2002 ranked #81 of 516 in nation (top 16%, #2 district).